Clinical Trials Browser

Approved for marketing × INDUSTRY × mobocertinib × Clear all

NCT04535557 2022-09-30

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Approved for marketing

Carcinoma, Non-Small-Cell Lung